REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...
A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...
Study Description A5384 is a trial for people who have or might have tuberculous meningitis (TBM). TBM is an infectious disease...
The purpose of this study is to develop and assess the efficacy of an integrated strategy that includes feasible and scalable...
